News Sentiment

ERAS sentiment intelligence

Erasca Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 18.53 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+0.3% over one week, +31.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend active 31.9% over four weeks
Fair value 343.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 39
Negative 16

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 7
GlobeNewswire 7
simplywall.st 6
PR Newswire 4
Moomoo 3
The Globe and Mail 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 30
Regulatory and legal 19
Earnings 10
Balance sheet 3
Analyst action 2
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 66
Investing.com Direct company coverage

Erasca reports phase 1 data for RAS inhibitor ERAS-0015

Erasca Inc. announced updated preliminary Phase 1 data for its investigational oral pan-RAS molecular glue, ERAS-0015, showing a 57% unconfirmed overall response rate in patients with RAS-mutant solid tumors, specifically KRAS G12X pancreatic ductal adenocarcinoma. The company pl

Tone
Positive 70/100
Event
Regulatory and legal
Published
13 Jul 2026 21:12
Source
Investing.com
Stock Titan Direct company coverage

Erasca, Inc. (NASDAQ: ERAS) sets up shelf to issue stock, debt and warrants

Erasca, Inc. (NASDAQ: ERAS), a clinical-stage precision oncology company, has filed an automatic shelf registration as a well-known seasoned issuer. This registration allows Erasca to offer various securities, including common stock, preferred stock, debt securities, and warrants

Tone
Neutral 50/100
Event
Balance sheet
Published
13 Jul 2026 20:12
Source
Stock Titan
Key Biscayne Portal Direct company coverage

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit

The Rosen Law Firm reminds purchasers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, of the August 10, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges Erasca and its executives made false and misleading

Tone
Negative 13/100
Event
Regulatory and legal
Published
13 Jul 2026 16:10
Source
Key Biscayne Portal
GlobeNewswire Direct company coverage

Levi & Korsinsky Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS

Levi & Korsinsky, LLP is encouraging investors in Erasca, Inc. (NASDAQ: ERAS) who suffered losses to contact their firm regarding a pending class action lawsuit. Investors who purchased ERAS securities between January 14, 2025, and April 26, 2026, may be eligible to recover damag

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 13:41
Source
GlobeNewswire
Investing.com India Direct company coverage

Goldman Sachs initiates Erasca stock coverage as early-stage biotech By Investing.com

Goldman Sachs has initiated coverage on Erasca Inc. (NASDAQ: ERAS) with an Early-Stage Biotech rating. Despite a significant surge in stock price over the past year, InvestingPro data suggests the company is overvalued. Erasca focuses on precision oncology, developing treatments

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 09:41
Source
Investing.com India
GlobeNewswire Direct company coverage

ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc.

The Rosen Law Firm is encouraging investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, to secure legal counsel before the August 10, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges

Tone
Negative 18/100
Event
Regulatory and legal
Published
12 Jul 2026 21:40
Source
GlobeNewswire
The National Law Review Direct company coverage

ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) and its officers. The lawsuit seeks to recover damages for investors who purchased Erasca securities between January 14, 2025, and April 26, 2026, alleging that the compa

Tone
Negative 29/100
Event
Regulatory and legal
Published
12 Jul 2026 12:11
Source
The National Law Review
The National Law Review Direct company coverage

ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP has reminded Erasca (NASDAQ: ERAS) investors of the upcoming August 10, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Erasca made false or misleading statements regarding its ERAS-0015 drug

Tone
Neutral 50/100
Event
Regulatory and legal
Published
11 Jul 2026 17:10
Source
The National Law Review
PR Newswire Direct company coverage

Erasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS

ClaimsFiler is reminding investors of Erasca, Inc. (NasdaqGS: ERAS) who suffered losses exceeding $100,000 to file lead plaintiff applications by August 10, 2026. This securities class action lawsuit alleges that Erasca and its executives made false and misleading statements rega

Tone
Negative 8/100
Event
Regulatory and legal
Published
11 Jul 2026 02:00
Source
PR Newswire
GlobeNewswire Direct company coverage

Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.

Robbins LLP is reminding stockholders about a class action lawsuit filed against Erasca, Inc. (NASDAQ: ERAS) for alleged non-disclosure of patent and trade secret infringement risks related to its drug candidate ERAS-0015. The lawsuit covers investors who purchased securities bet

Tone
Negative 29/100
Event
Regulatory and legal
Published
10 Jul 2026 19:09
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Does Erasca’s Shift Into Russell Growth Indexes (ERAS) Quietly Redefine Its Biotech Investment Story?

In June 2026, Erasca, Inc. transitioned from Russell value and microcap benchmarks to Russell growth indexes, including the Russell 2000 and 3000 Growth series. This reclassification reshapes how institutions categorize the biotech company, which currently has no revenue, signifi

Tone
Negative 35/100
Event
Earnings
Published
10 Jul 2026 17:40
Source
Simply Wall Street
Caledonian Record Direct company coverage

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with the Schall ...

The Schall Law Firm has announced a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) for alleged securities fraud, covering investors who purchased shares between January 14, 2025, and April 26, 2026. The lawsuit claims Erasca made false and misleading statements regardin

Tone
Negative 5/100
Event
Regulatory and legal
Published
10 Jul 2026 15:09
Source
Caledonian Record
GlobeNewswire Direct company coverage

ERAS Shareholder Alert: Erasca, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Erasca, Inc. (NASDAQ: ERAS) investors who purchased shares between January 14, 2025, and April 26, 2026. This alert concerns a securities class action lawsuit alleging that Erasca made materially false and/or misleading statem

Tone
Negative 20/100
Event
Regulatory and legal
Published
10 Jul 2026 12:40
Source
GlobeNewswire